Composite Inflammatory Score for Predicting Progression-Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First-Line Toripalimab Plus Axitinib.
- 1Department of Urology, The First People's Hospital of Jintan, Changzhou, Jiangsu, China.
- 2Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- 3Department of Nephrology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Abstract
Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy-based treatment. This single-center retrospective study included 237 patients who received first-line toripalimab plus axitinib therapy. Ten indices were natural-log transformed and standardized, and domain-based selection yielded a compact composite inflammatory score (COMP-IS), which was internally validated using 1000 full-pipeline bootstrap resamples. The primary endpoint was progression-free survival (PFS). During a median follow-up of 19.84 months for PFS, 124 events occurred. COMP-IS comprised the neutrophil-to-lymphocyte ratio, C-reactive protein-to-albumin ratio (CAR), and prognostic nutritional index. After adjusting for the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score, each standard deviation increase in COMP-IS was associated with shorter PFS (hazard ratio, 3.48; 95% confidence interval, 2.74-4.42). The apparent concordance index (C-index) for COMP-IS was 0.767, with a bootstrap-corrected C-index of 0.755, compared with corrected C-indices of 0.694 for CAR and 0.565 for the IMDC score. Adding IMDC to COMP-IS resulted in a corrected C-index of 0.756. In an exploratory post hoc comparison, the published Meet-URO risk groups had an apparent C-index of 0.593. COMP-IS demonstrated prognostic discrimination for PFS in this cohort; however, only internal validation was performed. Its clinical utility therefore remains uncertain, and independent external validation and prospective evaluation are needed before routine clinical use.
Related
- Development and temporal validation of an explainable machine learning model for predicting in-hospital diabetic foot ulcer in patients with type 2 diabetes using inflammatory–nutritional composite indices
- Opposing Natural Killer and Macrophage Associations Are Masked Within a CD16/IL-15/IL-15RA Composite Score in Metastatic Urothelial Carcinoma
- Lymphangioma Circumscriptum-Like Cutaneous Manifestation in Metastatic Colorectal Cancer: A Case Report Highlighting the Role of Dermatology in the Detection of Systemic Disease Progression.
- ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma
- Composite inflammatory indices and incident lung cancer risk in an exploratory statistical mediation analysis
BibTeX
@article{wu2026composite,
title = {{Composite Inflammatory Score for Predicting Progression-Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First-Line Toripalimab Plus Axitinib.}},
author = {Yun-Feng Wu and Jing-Suo Wang and Chuan-Ao Zhang and Fan Zhang and Zhi-Yu Zhang},
journal = {The Kaohsiung journal of medical sciences},
year = {2026},
month = oct,
doi = {10.1002/kjm2.70307},
url = {https://europepmc.org/article/MED/42910542},
note = {CC BY},
}
RIS
TY - JOUR
TI - Composite Inflammatory Score for Predicting Progression-Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First-Line Toripalimab Plus Axitinib.
AU - Yun-Feng Wu
AU - Jing-Suo Wang
AU - Chuan-Ao Zhang
AU - Fan Zhang
AU - Zhi-Yu Zhang
PY - 2026
DA - 2026/10/22
JO - The Kaohsiung journal of medical sciences
DO - 10.1002/kjm2.70307
UR - https://europepmc.org/article/MED/42910542
AB - Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy-based treatment. This single-center retrospective study included 237 patients who received first-line toripalimab plus axitinib therapy. Ten indices were natural-log transformed and standardized, and domain-based selection yielded a compact composite inflammatory score (COMP-IS), which was internally validated using 1000 full-pipeline bootstrap resamples. The primary endpoint was progression-free survival (PFS). During a median follow-up of 19.84 months for PFS, 124 events occurred. COMP-IS comprised the neutrophil-to-lymphocyte ratio, C-reactive protein-to-albumin ratio (CAR), and prognostic nutritional index. After adjusting for the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score, each standard deviation increase in COMP-IS was associated with shorter PFS (hazard ratio, 3.48; 95% confidence interval, 2.74-4.42). The apparent concordance index (C-index) for COMP-IS was 0.767, with a bootstrap-corrected C-index of 0.755, compared with corrected C-indices of 0.694 for CAR and 0.565 for the IMDC score. Adding IMDC to COMP-IS resulted in a corrected C-index of 0.756. In an exploratory post hoc comparison, the published Meet-URO risk groups had an apparent C-index of 0.593. COMP-IS demonstrated prognostic discrimination for PFS in this cohort; however, only internal validation was performed. Its clinical utility therefore remains uncertain, and independent external validation and prospective evaluation are needed before routine clinical use.
SN - 1607-551X
SN - 2410-8650
ER -